Migraine pain relief study for kids and teens
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision clinical trials.
This trial studies a medicine for stopping a migraine attack in children and teens. It may help families understand which treatment works best during acute (during-attack) migraine pain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have had migraine headaches for more than 6 months
- In the last 2 months, you had 1 to 8 moderate or severe attacks per month, lasting over 3 hours when untreated
- Migraine attacks happened at least 24 hours apart
- If you take preventive migraine medicine, the dose is stable for at least 12 weeks and will not change during the study (with a specific exception about certain biologic migraine shots)
- Child is between 6 and under 18 years old and weighs more than 40 kg (no 18th birthday during the study)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how safe ubrogepant is and whether it helps treat an individual migraine attack in children and teens. It focuses on measuring side effects and whether headaches improve 2 hours after taking the study medicine.
This study looks at ways to help children and teens with migraine headaches by testing a care approach that includes access to evidence-based treatment. It may help if your child has frequent migraine headaches and is starting (or not already on) certain migraine-preventive medicines.
This study follows kids and teens who already took part in an earlier migraine medication study to check long-term safety and comfort with oral ubrogepant tablets. It may help families understand whether this migraine tablet is safe to keep using over time.
This trial tests an oral medication called atogepant to see if it can prevent migraines in teens aged 12–17. It aims to reduce how often migraines happen and track any side effects.
This study tests whether an oral medicine called atogepant can reduce migraine activity in children ages 6–17 and checks its side effects. It’s meant for kids with episodic migraine (not the more constant types) who may benefit from preventive treatment.
This Phase 3 study checks the long-term safety of rimegepant, a migraine treatment, in children and teens. You might join if your child has had migraine for at least 6 months and still gets a certain number of moderate-to-severe migraine attacks.
Hear when a new Pediatric Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.